CoChat

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

Open access

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Abstract

Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain (ECD) mutations. Here we find that patients who experience greater and longer responses to EGFR blockade preferentially develop EGFR ECD mutations, while RAS mutations emerge more frequently in patients with smaller tumour shrinkage and shorter progression-free survival. In circulating cell-free tumour DNA of patients treated with anti-EGFR antibodies, RAS mutations emerge earlier than EGFR ECD variants. Subclonal RAS but not EGFR ECD mutations are present in CRC samples obtained before exposure to EGFR blockade. These data indicate that clonal evolution of drug-resistant cells is associated with the clinical outcome of CRC patients treated with anti-EGFR antibodies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms13665

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Clinical benefit of CRC patients treated with anti-EGFR therapy according to the emergence of EGFR ECD versus RAS mutations. (a) Response measured by RECIST criteria 1.1 in 27 CRC patients, according to the emergence of EGFR ECD versus RAS mutations detected in tumour tissue and/or plasma. Most patients with emergence of EGFR ECD mutations achieved a partial response, whereas patients with emergence of RAS mutations mostly had stable disease as best response (P=0.128 by Fisher's exact test). Cases with co-existence of EGFR ECD and RAS mutations were excluded from the group of RAS mutant tumours (RAS group) and included in the group of EGFR ECD mutant tumours (EGFR group). (b) Kaplan–Meier estimates of PFS according to the emergence of RAS mutations versus EGFR ECD mutations detected in tumour tissue and/or plasma. The hazard ratio for the RAS group (grey line) as compared with the EGFR group (red line) was 2.56 (95% CI, 1.06–6.21; P=0.013 by a stratified log-rank test). Median PFS time in the RAS group was 25.6 weeks (95% CI, 24–27), as compared with 44.6 weeks (95% CI, 38–49) in the EGFR group.
Figure 1 Clinical benefit of CRC patients treated with anti-EGFR therapy according to the emergence of EGFR ECD versus RAS mutations. (a) Response measured by RECIST criteria 1.1 in 27 CRC patients, according to the emergence of EGFR ECD versus RAS mutations detected in tumour tissue and/or plasma. Most patients with emergence of EGFR ECD mutations achieved a partial response, whereas patients with emergence of RAS mutations mostly had stable disease as best response (P=0.128 by Fisher's exact test). Cases with co-existence of EGFR ECD and RAS mutations were excluded from the group of RAS mutant tumours (RAS group) and included in the group of EGFR ECD mutant tumours (EGFR group). (b) Kaplan–Meier estimates of PFS according to the emergence of RAS mutations versus EGFR ECD mutations detected in tumour tissue and/or plasma. The hazard ratio for the RAS group (grey line) as compared with the EGFR group (red line) was 2.56 (95% CI, 1.06–6.21; P=0.013 by a stratified log-rank test). Median PFS time in the RAS group was 25.6 weeks (95% CI, 24–27), as compared with 44.6 weeks (95% CI, 38–49) in the EGFR group.CC BY · PubMed Central
Figure 2 Longitudinal analysis of plasma ctDNA collected during anti-EGFR therapy. Shades of black and grey indicate frequency of circulating RAS mutant alleles; and shades of red and orange indicate frequency of circulating EGFR mutant alleles. All patients achieved partial response or disease stabilization under EGFR blockade administered alone or in combination with standard chemotherapy. RAS mutant clones are apparent in the circulation months earlier than EGFR clones in all of the three cases. CT, computed tomography; PD, progressive disease; Pmab, panitumumab; PR, partial response; SD, stable disease.
Figure 2 Longitudinal analysis of plasma ctDNA collected during anti-EGFR therapy. Shades of black and grey indicate frequency of circulating RAS mutant alleles; and shades of red and orange indicate frequency of circulating EGFR mutant alleles. All patients achieved partial response or disease stabilization under EGFR blockade administered alone or in combination with standard chemotherapy. RAS mutant clones are apparent in the circulation months earlier than EGFR clones in all of the three cases. CT, computed tomography; PD, progressive disease; Pmab, panitumumab; PR, partial response; SD, stable disease.CC BY · PubMed Central
Figure 3 Selection of RAS and EGFR ECD mutations during development of resistance to EGFR blockade in CRC cells. Mutational profiles were used to monitor clonal dynamics of LIM1215 CRC cells under cetuximab treatment. Frequency of the NRAS G12C and EGFR S492R mutations at each time point are shown as determined by NGS. The frequencies presented were adjusted for gene copy number as it was determined by FISH analysis that LIM1215 has a duplication of the EGFR locus (7p.11.2) in the p-arm of chromosome 7 (Supplementary Fig. 5).
Figure 3 Selection of RAS and EGFR ECD mutations during development of resistance to EGFR blockade in CRC cells. Mutational profiles were used to monitor clonal dynamics of LIM1215 CRC cells under cetuximab treatment. Frequency of the NRAS G12C and EGFR S492R mutations at each time point are shown as determined by NGS. The frequencies presented were adjusted for gene copy number as it was determined by FISH analysis that LIM1215 has a duplication of the EGFR locus (7p.11.2) in the p-arm of chromosome 7 (Supplementary Fig. 5).CC BY · PubMed Central
Figure 4 Fitness of individual and double-mutated cells in the presence of cetuximab. (a) Sensitivity to cetuximab of LIM1215 parental, resistant pool and single-cell clones containing the indicated mutations. Cell populations and individual clones were treated with increasing doses of cetuximab for 6 days. Cell viability was measured by ATP assay and the mean calculated as % of untreated control. Error bars are s.d. of three independent experiments with three technical replicates. ***P<0.001 by unpaired two-tailed Student's t-test (NRAS+EGFR clone versus NRAS clone). (b) Western blot analysis of the indicated cells treated with 50 μg ml−1 of cetuximab and lysed after 2 h of treatment. Lysates were immunoblotted with the indicated antibodies. Vinculin was included as a loading control. Cetux, cetuximab.
Figure 4 Fitness of individual and double-mutated cells in the presence of cetuximab. (a) Sensitivity to cetuximab of LIM1215 parental, resistant pool and single-cell clones containing the indicated mutations. Cell populations and individual clones were treated with increasing doses of cetuximab for 6 days. Cell viability was measured by ATP assay and the mean calculated as % of untreated control. Error bars are s.d. of three independent experiments with three technical replicates. ***P<0.001 by unpaired two-tailed Student's t-test (NRAS+EGFR clone versus NRAS clone). (b) Western blot analysis of the indicated cells treated with 50 μg ml−1 of cetuximab and lysed after 2 h of treatment. Lysates were immunoblotted with the indicated antibodies. Vinculin was included as a loading control. Cetux, cetuximab.CC BY · PubMed Central
Figure 5 Emergence of RAS and EGFR ECD mutations in CRC cell populations. RAS and EGFR mutation frequencies were measured by ddPCR and are indicated for LIM1215 cells cultured in low-serum, chemotherapy, chemotherapy plus cetuximab and cetuximab-only conditions. R1 and R5 cetux indicate two resistant populations of LIM1215 generated independently. Cetux, cetuximab.
Figure 5 Emergence of RAS and EGFR ECD mutations in CRC cell populations. RAS and EGFR mutation frequencies were measured by ddPCR and are indicated for LIM1215 cells cultured in low-serum, chemotherapy, chemotherapy plus cetuximab and cetuximab-only conditions. R1 and R5 cetux indicate two resistant populations of LIM1215 generated independently. Cetux, cetuximab.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. Whitehead, R. H., Macrae, F. A., St Sohn, D. J. & Ma, J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J. Natl Cancer Inst. 74, 759–765 (1985).

Cited by

See all 221

Metadata

Authors
Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., Valtorta, E., Vidal, J., Bellosillo, B., Germano, G., Pietrantonio, F., Ponzetti, A., Albanell, J., Siena, S., Sartore-Bianchi, A., Di Nicolantonio, F., Montagut, C., & Bardelli, A.
Affiliations
  • Candiolo Cancer Institute (IT)
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
  • Hospital Del Mar (ES)
  • Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
  • Azienda Ospedaliero Universitaria San Giovanni Battista (IT)
  • University of Milan (IT)
Corresponding author
  • Montagut, Clara
  • Bardelli, Alberto
Venue
Nature Communications
Published
2016-12-08
Volume
7
Issue
1
Pages
13665-13665
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2560160922
Cited by
214
References
48
Citations by year
2026: 15 · 2025: 10 · 2024: 16 · 2023: 24 · 2022: 30 · 2021: 24 · 2020: 24 · 2019: 29 · 2018: 23 · 2017: 17 · 2016: 1
FWCI
12.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • Institutional Research Information System University of Turin (University of Turin) (submittedVersion, cc-by)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Repositori digital de la UPF (Universitat Pompeu Fabra) (submittedVersion, cc-by)
Funders
  • European Commission (635342, 115749, 602901)
  • Ministero della Salute
  • Associazione Italiana per la Ricerca sul Cancro (16788)
  • Fondazione Oncologia Niguarda Onlus
  • Instituto de Salud Carlos III (RD12/0036/0051, DTS15/00048, 2014SGR740, PIE15/00008, PI15/00457, PI15/00146, 00048)
  • European Regional Development Fund (PIE15/00008, PI15/00146, RD12/0036/0051)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
colorectal cancer, EGFR inhibition, RAS mutations, cetuximab, panitumumab, anti-EGFR monoclonal antibody, drug resistance, clonal evolution, progression-free survival, tumor shrinkage
MeSH terms
Antineoplastic Agents, Immunological, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Mutation, Genes, ras, Colorectal Neoplasms, Genes, erbB-1, Drug Resistance, Neoplasm, Clonal Evolution, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.